Institute for Wealth Management LLC. purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 27,713 shares of the company’s stock, valued at approximately $261,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Quadrant Capital Group LLC lifted its holdings in Elanco Animal Health by 281.7% during the 4th quarter. Quadrant Capital Group LLC now owns 2,706 shares of the company’s stock worth $33,000 after purchasing an additional 1,997 shares during the last quarter. UMB Bank n.a. lifted its holdings in Elanco Animal Health by 26.9% during the 4th quarter. UMB Bank n.a. now owns 3,747 shares of the company’s stock worth $46,000 after purchasing an additional 795 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Elanco Animal Health by 381.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,229 shares of the company’s stock worth $52,000 after purchasing an additional 3,350 shares during the last quarter. CKW Financial Group grew its stake in shares of Elanco Animal Health by 91.7% in the fourth quarter. CKW Financial Group now owns 4,600 shares of the company’s stock valued at $56,000 after acquiring an additional 2,200 shares in the last quarter. Finally, Captrust Financial Advisors grew its stake in shares of Elanco Animal Health by 57.0% in the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after acquiring an additional 977 shares in the last quarter. Institutional investors and hedge funds own 94.81% of the company’s stock.
Elanco Animal Health Trading Down 0.1 %
ELAN stock opened at $10.05 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 2.25 and a debt-to-equity ratio of 0.75. Elanco Animal Health Incorporated has a 52 week low of $7.88 and a 52 week high of $20.97. The business has a 50-day simple moving average of $9.26 and a 200 day simple moving average of $10.66.
Elanco Animal Health (NYSE:ELAN – Free Report) last issued its earnings results on Tuesday, May 9th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.29 by $0.16. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.18 billion. Elanco Animal Health had a negative net margin of 0.49% and a positive return on equity of 8.21%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.36 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.8 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Barclays upgraded shares of Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $14.00 price target on the stock in a research note on Thursday, April 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $15.40.
About Elanco Animal Health
(Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elanco Animal Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Elanco Animal Health wasn’t on the list.
While Elanco Animal Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report